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ABSTRACT
Objectives: Copeptin has been reported to play an important role in metabolic response in women with PCOS. However, 
the optimal cut-off value for detecting subjects with insulin resistance (IR) remains undetermined. We investigated whether 
copeptin can serve as an indicator of IR and tried to determine the optimal cut-off value of plasma copeptin concentration 
in detecting subjects with PCOS and IR.
Material and methods: We carried out a case-control study on 158 women with PCOS and HOMA-IR < 2.5, 96 women 
with PCOS with HOMA-IR ≥ 2.5, and 70 healthy volunteers. Plasma copeptin, as well as hormonal, biochemical, metabolic, 
and IR parameters, were measured. To investigate whether copeptin allows IR to be predicted in PCOS, we used logistic 
regression models and ROC curve analysis.
Results: Median plasma copeptin concentration was the highest in the women with PCOS and HOMA-IR ≥ 2.5. Logistic 
regression analysis revealed that copeptin was the strongest predictor of HOMA ≥ 2.5 (OR: 53.34 CI 7.94–358.23, p < 0.01). 
Analysis of ROC curves indicated that the cut-off value above 4 pmol/L of plasma copeptin concentration had high (99%) 
specificity but very low (21%) sensitivity in diagnosing of IR (AUC 0.607 (95% CI 0.53–0.68.
Conclusions: Our findings suggest that copeptin is associated with IR in PCOS patients, but due to low sensitivity should 
not be considered as a marker of IR.
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is a heterogeneous en-
docrine disease with an estimated occurrence rate of 5–10% 
in women of reproductive age [1]. Although metabolic dis-
turbances, such as obesity and insulin resistance (IR), play 
an important role in the pathogenesis of PCOS, they do not 
currently form part of the diagnostic criteria. Approximate-
ly 50–60% of women with PCOS are overweight or obese, 
and IR is found in 50% of women with PCOS, irrespective 
of obesity [2]. Women with PCOS have increased cardio-
metabolic risk — that is, their risk of developing diabetes, 
hypertension, dyslipidemia, and cardiovascular disorders is 
greater than the risk within the population as a whole [3]. 
It is known that IR is the underlying cause for all these car-
diovascular and metabolic disorders. Attention has recently 
been drawn to the role of arginine vasopressin (AVP) in con-
trolling glucose homeostasis, the pathogenesis of IR, and the 
development of diabetes [4–6]. The activation of the hypo-
thalamic-pituitary-adrenal (HPA) axis by AVP under chronic 
psychosocial stress stimulates the secretion of cortisol by 
activating V1a receptors, which interferes with insulin activity 
while stimulating glucagon secretion and glycogenolysis [7]. 
This process subsequently leads to an increase in blood glu-
cose. By activating the V1b receptors on chromaffin cells in 
the adrenal medulla, AVP also increases epinephrine, which 
contributes to the development of hyperglycemia through 
glycogenolysis in the liver [7]. Increased AVP, as a result of 
the resistance of AVP to the V1a receptor, may also contrib-
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ute to IR and to the development of diabetes mellitus (DM) 
by stimulating the V1b receptor [8]. Because of its short 
half-life and instability, AVP is difficult to measure. Copeptin, 
the C-terminal fragment of provasopressin, is formed in the 
same quantities as AVP and, as a result of the processes that 
activate it, has been found to be a stable and sensitive sur-
rogate marker for AVP release [9].
Recently, it has been demonstrated that plasma co-
peptin concentrations are elevated in plasma of PCOS pa-
tients. Copeptin thus appears to have an important role in 
metabolic response and in the subsequent development 
of atherosclerosis in insulin-resistant, hyperandrogenemic 
PCOS patients [10, 11]. However, the optimal cut-off value 
for detecting subjects with metabolic disorders remains 
undetermined. 
Objectives 
The main aim of the study was to investigate whether 
copeptin can serve as an indicator of IR, and secondly, to 
determine the optimal cut-off value of plasma copeptin 
concentration in detecting subjects with PCOS and IR.
MATERIAL AND METHODS 
The study included 254 women with PCOS, aged 18–37 
years, and hospitalized in the Department of Reproduc-
tive Medicine and Gynecology at the Pomeranian Medical 
University, Szczecin, and in the Infertility and Reproductive 
Endocrinology Division of Poznań University of Medical 
Sciences in the years 2010–2012. Women with PCOS were 
divided into two groups, depending on the presence of 
IR: the PCOS(+)IR group consisted of women with a ho-
meostasis model assessment for IR index (HOMA-IR) ≥ 2.5, 
while the PCOS(-)IR group included only patients with HO-
MA-IR < 2.5. The study was approved by the Pomeranian Med-
ical University Ethics Committee (No. KB-0012/41/11). The 
patients were informed of the plan and purpose of the study 
and gave their written informed consent.
The diagnosis of PCOS was confirmed when at least two 
of the three diagnostic criteria were present, according to the 
Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Work-
shop Group [12]. Clinical hyperandrogenism was defined 
as a presence of hirsutism (a modified Ferriman-Gallwey 
score ≥ 8) with or without acne. Metabolic syndrome (MetS) 
was defined according to the IDF criteria by waist circumfer-
ence > 80 cm and at least two of the remaining features: 
1. Triglyceride (TG) level: ≥ 150 mg/dL or specific treatment 
for this lipid abnormality; 2. HDL cholesterol level: < 50 mg/dL 
or specific treatment for this lipid abnormality; 3. Systolic 
blood pressure ≥ 130 mmHg and diastolic blood pressure 
BP ≥ 85 mmHg, or treatment of previously diagnosed hy-
pertension; 4. Fasting plasma glucose (FPG) ≥ 100 mg/dL or 
previously diagnosed type-2 diabetes [13].
The control group consisted of 70 healthy, normally 
menstruating, age-matched hospital staff and medical 
students. We included only those subjects who met the 
following inclusion criteria: eumenorrhea, no medical condi-
tions requiring pharmacological treatment, and no apparent 
abnormalities in physical examination.
Assessment of clinical variables
The patients’ BMIs were calculated from the weight and 
height measurements, based on the recommendations of 
the World Health Organization [14]. Waist and hip circumfer-
ence measurements were also carried out. Blood pressure 
(BP) was measured using a standard mercury sphygmoma-
nometer with an appropriate cuff size after a resting period 
of at least 30 min. Hypertension was defined according 
to the criteria of the Seventh Report of the Joint National 
Committee on the Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure as systolic BP ≥ 140 mmHg 
and diastolic BP ≥ 90 mmHg [15]. In the early follicular phase, 
between days 3 and 5 of the cycle, transvaginal ultrasound 
scans were performed in all patients. Polycystic morphology 
of ovaries was identified by the sonography according to 
the established criteria recommended in the literature [12].
Blood sample collection
Blood sampling was performed in the early follicular 
phase of the spontaneous or progesterone-induced men-
strual cycle (between cycle days 3 and 5), after 12 h over-
night fasting. Serum levels of FSH, LH, estradiol, prolactin, 
TSH, SHBG, and insulin were determined by specific electro-
chemiluminescence assays (automated Elecsys 2010 immu-
noanalyzer, Roche Diagnostics GmbH). The same method, 
with the use of Cobas 6000 equipment and Roche reagents, 
was applied to determine total testosterone levels. Levels 
of serum total cholesterol, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL), and triglycerides (TG) were 
determined by semiautomated enzymatic methods (auto-
mated Cobas Integra 400Plus analyzer, Roche Diagnostics). 
The chemiluminescence method was used to determine the 
levels of androstenedione, DHEA-S, and hs-CRP with the use 
of Immulite equipment and Siemens reagents). The plasma 
glucose concentration was determined using the glucose 
oxidase/peroxidase method. All the basic hormonal and 
biochemical measurements were performed at the Central 
Laboratory of University Hospitals.
The free androgen index (FAI) was calculated as the 
serum testosterone (nmol/L) x 100/SHBG (nmol/L) ratio [16]. 
IR was diagnosed according to the homeostasis model as-
sessment for IR index (HOMA-IR), and the value was calcu-
lated using the following formula: fasting plasma glucose 
(mmol/L) × fasting serum insulin (mU/mL)/ 22.5. The cut-off 
value for IR was HOMA-IR ≥ 2.5 [17].
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Copeptin assay
Blood samples were taken into EDTA tubes and cen-
trifuged at 3000 G for 10 min. After that, 500 μg of the ob-
tained plasma was separated into a clean test tube with the 
addition of 5 μl aprotinin. The plasma samples were stored 
at -80°C until analysis. Copeptin levels were measured in 
duplicate using competitive enzyme immunoassay (#EK-
065-3 Copeptin-Human EIA Kit, Phoenix Pharmaceuticals), 
carried out in line with the manufacturer’s recommendations 
and using the average values from two measurements. The 
analytical sensitivity was 0.16 ng/mL. The coefficient of 
intra-assay repeatability was below 10%, whereas the coef-
ficient of interassay repeatability for this test was < 15%. No 
cross-reactions were observed in this method.
Statistical analysis 
Since the distributions of most quantitative variables 
were significantly different from normal, the difference 
between the groups was tested using the Kruskal-Wallis 
(test) ANOVA. The Fisher exact test was employed to com-
pare qualitative variables. Where a significant difference 
was found in the Kruskal-Wallis test, the post hoc test with 
the Bonferroni adjustment was applied to determine the 
significant differences. The strength of the correlation be-
tween quantitative variables was measured using the Spear-
man rank correlation coefficient (Rs). 
A variety of statistical methods were used to investigate 
whether copeptin can predict insulin resistance in PCOS. We 
first used linear and logistic regression models. Univariate 
linear regression analyses were performed with the copep-
tin level as the independent variable and HOMA-IR as the 
dependent variable. Subsequently, these associations were 
adjusted for covariates that could potentially confound 
in this association, using multivariable logistic regression 
models. Multivariable models were built stepwise and the 
following statistically significant parameters were included: 
age, BMI > 25 kg/m2, SBP, HDL and copeptin > 4.0 pmol/L. 
Secondly, a receiver operating characteristic (ROC) anal-
ysis was performed to assess the diagnostic value of copep-
tin as a marker of insulin resistance. P-values < 0.05 were 
considered statistically significant. Statistica 10 software 
(StatSoft, USA) was used for the calculations. 
Additionally, to examine the possible correlation be-
tween copeptin concentration and the prevalence of MetS, 
the subjects were stratified by quartiles of copeptin con-
centration. 
RESULTS 
The baseline characteristics of the three study groups 
are shown in Table 1. The groups differed statistically in 
terms of anthropometric measurements (BMI, waist cir-
cumference, and WHR), chosen hormonal indices (SHBG, 
FAI), blood pressure, and HDL and LDL cholesterol. As might 
be expected, the PCOS(+)IR group had the highest fast-
ing plasma glucose concentration and the highest fast-
ing plasma insulin levels. Plasma copeptin concentration 
was the highest in the PCOS(+)IR group (median 1.64, in-
terquartile range [IR 0.98–3.27] pmol/L), moderate in the 
PCOS(-)IR group (1.28 [IR 0.93–2/02] pmol/L), and the lowest 
(0.97 pmol/L [IR 0.76–1.14]) in the control group (p = 0.014). 
Interestingly, significant differences were found between 
studied groups regarding the prevalence of MetS, which 
was present in 37.5% of PCOS(+)IR, 10.1% of PCOS(-)IR, and 
17.1% of controls. 
Spearman rank correlation coefficient analysis showed 
no correlation between the plasma copeptin concentra-
tion and anthropometric measurements. Plasma copeptin 
was inversely correlated with FG score (-0.17; p < 0.01), and 
positively correlated with fasting insulin (0.18; p < 0.005), 
HOMA-IR (0.19; p < 0.005), and systolic and diastolic BP(0.14; 
p < 0.05; 0.17; p < 0.01). Even though the prevalence of MetS 
was different, we failed to find any correlation between MetS 
and copeptin (p = 0.4).
In the logistic regression model, the strongest predic-
tor of elevated HOMA-IR ≥ 2.5 was copeptin (OR: 53.34 CI 
7.94–358.23, p < 0.01). The others were BMI ≥ 25 m/kg2 
(OR: 4.22 CI: 1.85–9.64, p < 0.01) and SBP (OR: 1.02 CI: 1.00–
1.05, p = 0.03). Age (OR: 0.86 CI: 0.80–0.93, p < 0.01) and HDL 
(OR: 0.96 CI: 0.93–0.98, p < 0.01) were negatively associated 
with HOMA-IR ≥ 2.5. 
The ROC curve assessing the ability of copeptin to distin-
guish between women with and without IR had an AUC of 
0.607 (95% CI 0.53–0.68) and a threshold value of 4 mmol/L 
or higher to identify insulin-resistant women in the PCOS 
group (Fig. 1). At this cut-off point, copeptin assay showed 
very high (99%) specificity to identify IR in women with 
PCOS, but low (21%) sensitivity.
DISCUSSION 
Although IR and its metabolic consequences are not 
included in the diagnostic criteria of PCOS, it is well known 
that they play an important role in the pathogenesis of 
this disease. Copeptin, the C-terminal fragment of prov-
asopressin, is formed in equal quantities as vasopressin 
(AVP) and, as a result of processes that activate it, has been 
suggested as a new and promising marker of IR and MetS. 
Until recently, it was believed that AVP’s only role was its 
effect on the water-electrolyte balance of the body. It has 
since been shown that, in response to stress factors, AVP 
and corticotrophin-releasing hormone (CRH) stimulate 
the secretion of adrenocorticotrophic hormone (ACTH), 
which increases the secretion of adrenocortical hormones 
— mainly cortisol and, to a smaller extent, androgens and 
aldosterone [18,19]. Although under physiological condi-
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tions CRH is a stronger stimulator of ACTH secretion, the 
synergistic effect of both neurohormones is over 30 times 
greater than that of CRH alone. It has been demonstrated 
that the role of AVP is greater under chronic stress. [19] 
There is an increase in the number of neurons expressing 
both CRH and AVP, and the amount of V1bR increases in the 
pituitary, with reduced CRH receptor. This effect is resistant 
to glucocorticoid feedback, suggesting crosstalk between 
the AVP and hypothalamic-pituitary-adrenal system that 
could be relevant to insulin resistance and diabetes develop-
ment [20, 21]. Research on an animal model involving mice 
lacking V1aR showed display-impaired glucose tolerance 
and development of IR with increased AVP levels, whereas 
mice that lacked V1bR had lower fasting plasma glucose 
level and increased insulin sensitivity [22, 23]. Based on 
these studies, it is assumed that the abnormal effects on 
V1aR lead to increased AVP levels, which then stimulate 
VbR, leading to the development of disorders causing IR and 
diabetes. Saleem et al. [7] first report the cross-sectional as-
sociation between high plasma copeptin levels, measures of 
IR, and the presence of MetS. The researchers reported that 
plasma copeptin levels correlate significantly with BMI, fast-
ing plasma glucose, insulin level, HOMA-IR, and triglyceride 
level, and inversely with HDL-cholesterol. Furthermore, the 
multiple regression analysis that was adjusted for age and 
sex, plasma copeptin levels in the third and fourth quartiles 
were significantly associated with higher odds of having 
MetS. It has been estimated that the activation of the HPA 
axis by AVP in chromic psychosocial stress may be one of the 
mediators of its association with IR. It was concluded that 
such neuroendocrine dysregulation may lead to higher 
cortisol, decreased energy expenditure, increased appetite 
and food consumption, increased peripheral vascular resist-
ance, and increased insulin levels. The reported study [7] 
Table 1. Clinical characteristics of the control, PCOS(-)IR, and PCOS(+)IR groups
Controls 
n = 70
PCOS(-)IR [HOMA < 2.5]
n = 158
PCOS(+)IR [HOMA ≥ 2.5]
n = 96 p-value
Age [years] 28 (22–30) 28 (25–31) 26.5 (23–30.5) ns
BMI [kg/m2] 25.3 (22.1–28.7) 22.7(20.7–26.5) 28.8 (24.8–32) p < 0.001
Waist circumference [cm] 80.5 (71–91) 75 (69–85) 91 (78–101) p < 0.001
WHR 0.79 (0.74–0.86) 0.78 (0.74–0.84) 0.83 (0.77–0.88) p < 0.001
FSH [mIU/mL] 4.9 (3.96–6.25) 5.86 (5–6.84) 5.51 (4.74 -6.77) ns
LH [mIU/mL] 6.04 (4.99–7.15) 9.32 (5.8–12.7) 7.74 (5.39–12.3) ns
Estradiol [pg/mL] 47.1 (32.5–70) 46.4 (34.4–64.1) 43 (33.5–61.6) ns
Prolactin [ng/mL] 15 (9.96–19.3) 13.8(9.85–18.8) 16(10.5–22.1) ns
TSH [μIU/mL] 1.63 (1.2–2.05) 1.9 (1.29–2.45) 1.94 (1.31–2.46) ns
Testosterone [ng/mL] 0.35 (0.25–0.46) 0.46 (0.33–0.56) 0.46 (0.35–0.61) ns
SHBG [nmol/L] 55.4 (39.9–73.4) 45.73 (30.5–64.3) 28.3 (19.25–50.3) p < 0.001
FAI 2.45 (1.34–3.57) 3.65 (2.18–5.48) 5.43 (3.48–9.17) p < 0.001
DHEA-S [μg/dL] 159 (135–181) 247 (198–332) 287 (212–361) ns
FG Score 0 (0–0) 8 (4–11) 8 (3–10) ns
Fasting Glucose [mg/dL] 85 (81–89) 89 (83–94) 94.1 (88.7–98) —
Fasting Insulin [μIU/mL] 6.83 (5.23–9.43) 5.97 (4.67–8.08) 14.8 (12.9–19.1) —
HOMA - IR 1.42 (1.07–2.06) 1.33 (0.98–1.83) 3.51 (2.96–4.48) —
Copeptin [pmol/L] 0.97 (0.76–1.14) 1.28 (0.93–2.02) 1.64 (0.98–3.27) p < 0.05
SBP [mmHg] 120 (110–130) 120 (106–130) 130 (120–140) p < 0.001
DBP [mmHg] 78.5 (70–85) 70 (60–80) 80 (70–85) p < 0.001
Total Cholesterol [mg/dL] 165 (145–187) 186 (164–209) 188 (168–211) ns
HDL Cholesterol [mg/dL] 59.5 (47–69) 66.5 (56–78) 51.5 (43.1–61.5) p < 0.001
LDL Cholesterol [mg/dL] 99 (82–116) 102 (85.8–120) 110 (97–133) p < 0.05
Triglycerides [mg/dL] 73 (55–99) 72 (57.9–94.1) 103 (72.2–142) p < 0.001
Metabolic syndrome [%] 17.1% 10.1% 37.5% p < 0.001
hs-CRP [mg/L] 1.3 (0.79–2.59) 1.31 (0.69–3.4) 2.05 (0.82–4.9) ns
Values are expressed as medians (interquartile range); p-values were calculated using the Mann-Whitney post hoc U-test with the Bonferroni adjustment; p < 0.05 was 
considered statistically significant
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included a large cohort that was much older than ours 
(with a mean age of 59 years) with familial hypertension 
and a relatively high prevalence of MetS (around 50%). 
In agreement with this study, we observed that plasma 
copeptin levels correlate with IR, but (unlike the results 
of Saleem et al.) not with full-blown MetS. Interestingly, 
a cross-sectional study extended the findings of Saleem et 
al. to a large population-based sample by showing that high 
copeptin levels are not only associated with the clustering 
of the MetS components, but that there is also an independ-
ent relationship with the core components of the syndrome 
— i.e., with hypertension and abdominal obesity [24]. Our 
results suggest that higher plasma copeptin levels are posi-
tively correlated with systolic and diastolic BP, but not with 
full-blown MetS. The differences may be due to significant 
differences in population characteristics. We speculate that 
absence of MetS among our subjects is due to the young 
age. Furthermore, we used different criteria (the IDF cri-
teria) to diagnose MetS; these are more frequently used 
in Europe. Interestingly, Abbasi et al. have shown that the 
association of plasma copeptin with the risk of developing 
DM was stronger in women than in men, which contradicts 
the previous findings [24, 25]. Researchers have suggested 
that, because of lower tolerance to changes in AVP levels in 
women than in men, plasma copeptin both alone and along 
with the existing biomarkers such as glucose and hs-CRP 
significantly improved the risk prediction for diabetes in 
women, but not in men [26–28].
Our study aimed to assess the associations of copeptin 
concentration with well-known IR markers in women with 
PCOS. We have shown that plasma copeptin levels mark-
edly increased in PCOS patients as compared with healthy 
women, with special emphasis on the PCOS(+)IR group. This 
finding is in agreement with the report of Karbek et al. [10], 
the only study published to date that had considered co-
peptin in PCOS. Other researchers have reported increased 
copeptin levels and their positive correlation with fasting 
insulin, triglyceride, free testosterone, HOMA-IR, and ca-
rotid intima media thickness. The above study [10] included 
only a relatively small group of forty women with PCOS 
and investigated the correlation between copeptin and 
the progression of atherosclerosis in PCOS patients. This 
study demonstrated that copeptin concentrations increase 
in PCOS patients and are associated with IR. However, the 
authors did not show whether copeptin can be an indica-
tor of IR, nor did it determine the optimal cut-off value 
of plasma copeptin in detecting subjects with metabolic 
disorders. In agreement with the results of Krabek et al., 
plasma copeptin levels were significantly higher in PCOS 
than in the non-PCOS group and positively correlated with 
fasting insulin level, HOMA-IR, and FG score. 
In a large prospective cohort study, Enhorning et al. 
reported that elevated copeptin predicts increased risk 
of DM independently of established clinical risk factors, 
including fasting glucose and insulin [8]. The association 
between copeptin at baseline and the incidence of DM was 
independent of the incidence of abdominal obesity and 
vice versa; it is thus possible that AVP independently trig-
gers two different pathways leading to DM and abdominal 
obesity. Despite this, there is a possibility that the primary 
elevation of AVP caused by an increase in abdominal fat 
deposition can lead to the development of DM. Moreover, 
copeptin may better signal DM susceptibility earlier in the 
prediabetes state, which would be particularly useful in 
individuals with normal fasting glucose levels, who are likely 
to be less closely monitored than patients with impaired 
fasting glucose [4, 5]. Because PCOS is a risk factor for the 
development of type-2 DM, assessing the clinical utility of 
novel biomarkers such as copeptin would seem to be very 
important in this group of patients.
Our study showed copeptin to be associated with the 
risk of increased HOMA IR ≥ 2.5 in PCOS patients. The ROC 
analysis implies that copeptin levels above 4 pmol/L predict 
IR in PCOS patients with a specificity of 99%, meaning that 
almost all patients with that level and above have IR, how-
ever low sensitivity of 21% implies that 79% of IR women 
with PCOS may also have lower than 4 pmol/L copeptin 
levels. Therefore, copeptin cannot serve as a good marker 
for IR in our study group. Also, AUC value 0.607 reveals that 
copeptin levels are relatively weak surrogate of IR. 
This study has some limitations. First, it was observa-
tional, so we could not establish the temporal changes in 
plasma copeptin, its relationship with preexisting metabolic 
Figure 1. Receiver operating characteristics (ROC) curve assessing the 
ability of copeptin to distinguish between women with and without IR
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risk factors, or the future development of complications. Sec-
ond, the number of individuals in the control group was 
relatively low, and larger studies are needed to confirm 
our findings. We did not measure either psychosocial stress 
in the participants or plasma levels of cortisol — the final 
mediator of a perturbed HPA axis. In our study, we did not 
use ambulatory BP measurement, which has been shown 
to be more useful than the causal or office BP measure-
ment [29]. BP, if measured once during the day at a clinical 
examination, may give overestimated values in patients 
with white-coat syndrome. Finally, IR was reported based 
on HOMA-IR values. Although the gold standard for estab-
lishing IR is the euglycemic-hyperinsulinemic clamp, this 
elaborate procedure is not suitable as a screening method. 
The HOMA-IR calculation correlates very well with the eug-
lycemic-hyperinsulinemic clamp result and is often used as 
a surrogate marker [30]. However, the cut-off or threshold 
values for HOMA-IR have not been established. It is well 
known that the development of IR occurs on a physiological 
continuum. Our choice of the value 2.5 is based on origi-
nal HOMA research and previous work with PCOS patients 
[17, 31, 32].
CONCLUSIONS 
Our data suggest that  copeptin is associated with IR 
in PCOS patients, but copeptin measurements in plasma 
have very low sensitivity in detecting IR in this group of pa-
tients. Further work is necessary to improve our understand-
ing of the role of AVP in IR and metabolic disorders in PCOS.
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